Compare Celsius Holdings, Inc. (CELH) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs DexCom, Inc. — how do they compare? Celsius Holdings, Inc. trades at $27.12 (market cap $7.11B), while DexCom, Inc. trades at $89.43 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 4.8× Celsius Holdings, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | DXCM | |
|---|---|---|
Market Cap | $7.11B | $33.79B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $89.53 |
52-Week Low | $23.77 | $54.84 |
Enterprise Value | $8.90B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.21, down 2.02% on the day, with technical indicators signaling a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates of $0.4139, while revenue grew 11% year-over-year. Recent news highlights leadership changes and an ongoing shareholder investigation. The stock faces pressure from slowing core-brand growth but benefits from strong analyst support and a partnership with PepsiCo.
Outlook: High growth potential via international expansion and PepsiCo distribution, but execution risks and margin pressures persist. Risks include competitive threats and delayed growth projections. Analyst consensus is strongly bullish with a $44.08 price target, suggesting significant upside if operational challenges are overcome.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
